This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Article

Monitoring Metabolic Side Effects

Daniel E. Casey, MD; Dan W. Haupt, MD; John W. Newcomer, MD; David C. Henderson, MD; Michael J. Sernyak, MD; Michael Davidson, MD; Jean-Pierre Lindenmayer, MD; Steven V. Manoukian, MD, FACC; Mary Ann Banerji, MD; Harold E. Lebovitz, MD; and Charles H. Hennekens, MD

Published: May 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

While precise mechanisms underlying the glucose dysregulation and dyslipidemia during antipsychotic treatment are not yet fully elucidated, available data underscore the need for clinicians to be informed about weight, glucose, and lipid levels in patients taking atypical antipsychotics.

Glucose and insulin metabolism in humans can be assessed by several different methods, which can be listed in an approximate rank order ranging from least to most sensitive: random plasma glucose, glycated hemoglobin (A1C), fasting plasma glucose, homeostasis model assessment insulin resistance, postprandial glucose, oral glucose tolerance test (OGTT) and intravenous glucose tolerance test (IVGTT), frequently sampled IVGTT with Minimal Model analysis, and hyperinsulinemiceuglycemic and hyperglycemic clamps. Random plasma glucose offers limited sensitivity and may be falsely reassuring. In addition, no American Diabetes Association (ADA) or WHO criteria exist to diagnose impairments in glucose metabolism based on random plasma glucose levels in otherwise asymptomatic patients.’ ‹’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Metabolic Disorder , Side Effects-Medication

References